• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·EVERESTO.BO
Share

Everest Organics Limited Stocks

₹ 296Last Updated 27.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₹ 29.21M

₹ 296
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Everest Organics Limited is a pharmaceutical enterprise specializing in the production of bulk drugs. Its product line encompasses compounds such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, and Benzimadizole. Additionally, the company manufactures and exports active pharmaceutical ingredients (APIs) and their intermediates from its facilities in India, supplying these to formulation companies worldwide. The firm was founded on February 19, 1993, and its headquarters are located in Hyderabad, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 08:00

Europe's richest man regrets selling his Netflix and Google shares too early

29.07.2026 08:00

Ford Raises Profit Forecast for the Second Time This Year: Are the Aluminum Problems Behind It?

29.07.2026 04:16

The U.S. announced that it had intercepted Iranian missiles. Oil prices surged 4%, halting their decline

29.07.2026 02:06

The U.S. has restricted imports of humanoid robots. Which companies will be affected by this?

29.07.2026 01:14

July Could Be the Worst Month for Chipmakers' Stocks Since the Dot-Com Era

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026